NCT00095667View on ClinicalTrials.gov

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2007

Conditions
Recurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

lapatinib ditosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00095667 - Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter